Commercial opportunities
Telethon Kids is seeking partners to develop and commercialise our technology opportunities. We are looking for investment, collaboration and licensing partners for our technologies. Below are the list of opportunities available for partnering. Please contact us at commercialisation@telethonkids.org.au if you wish to discuss any of these opportunities, or any other areas of commercial interest.
| Therapeutic | ||||||
| Technology name | Disease | Modality | Mechanism of Action | Development stage | Partnering available | |
|---|---|---|---|---|---|---|
| Immunotherapy Gel | Oncology Solid Tumors | dsRNA | TLR 3 agonist | Pre-clinical | Yes | |
| Epithelial Cell Repair | Asthma IBD IPF | Small molecule | Undisclosed | Hit discovery | Yes | |
| SpritzOM | Otitis Media | Live biotherapeutic | Undisclosed | Pre-clinical | Yes | |
| Taste Masking Product | Pain/anxiety relief | Small molecule reformulation | NA | Regulatory | Yes | |
| Bacteriophage Therapy | AMR | Live biotherapeutic | Phage | Pre-clinical | Yes | |
| Diagnostic Tools | ||||
| Technology name | Disease | Technology | Development stage | Partnering available |
|---|---|---|---|---|
| VUS Diagnosis Pipeline for Rare Genetic Disease | Genetic disease gene mutation | Next Generation Sequencing | In development | Yes |
| PoC Antibiotic Resistance Test | Strep A | Isothermal DNA Amplification | In development | Yes |
| Social and behavioural sciences | |
| Technology name | Description |
|---|---|
| QI-disability | QI-disability was developed to specifically assess the quality of life of children and adolescents with intellectual disability. It is available for licensing as an outcome measure for clinical trials. Find out more. |
| Friendly Schools | Friendly Schools helps build critical social and emotional skills, create positive, safe and supportive learning environments, and significantly reduce bullying in both primary and secondary schools. Find out more. |
| CUES Autism Group Therapy |
Group therapy for parents or other primary caregivers that helps families understand how to support and mange their child’s challenges with uncertainty in everyday environments. |
| Inklings |
Inklings is a program for babies aged 6-18 months who are showing early differences in their social interaction and communication development. Find out more. |
| Digital health and software solutions | |||
| Technology name | Description | Development stage | Partnering available |
|---|---|---|---|
| Virtual WA | Modelling software that uses big data to map out physical and social geography. | Preliminary validation | Yes |
| AI Platform for Articulating Methods and Reason | Software that accurately, equitably, and automatically interprets highly complex and multi-dimensional data. | Proof of feasibility | Yes |
| Act1ve app Diabetes type 1 | App that contains exercise guidelines and tailored advice specifically for young people living with T1D. |
Prototype |
Yes |
The Team
Alex Hart
Acting Head, Innovation
alex.hart@telethonkids.org.au
0401 190 202
Dr Renaud Quantin
Commercialisation Manager
renaud.quantin@telethonkids.org.au
0413 847 834
David Menegola
Commercialisation Officer
david.menegola@telethonkids.org.au
0448 832 970
Ashley Schoof
Commercialisation Officer
ashley.schoof@telethonkids.org.au
0432 848 547
About Telethon Kids Institute
Telethon Kids Institute is one of the largest and most successful medical research institutes in Australia. We've created a bold blueprint that brings together community, researchers, practitioners, policy makers and funders, who share our vision to improve the health and wellbeing of children through excellence in research.
The Institute is headed by leading paediatrician and infectious diseases expert Professor Jonathan Carapetis, with Founding Director Professor Fiona Stanley now Patron.
Telethon Kids is independent and not-for-profit. The majority of funding comes from our success in winning national and international competitive research grants. We also receive significant philanthropic support from corporate Australia and the community.